<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT924-7067</title>
	</head>
	<body>
		<main>
			<p>921118 FT  18 NOV 92 / International Company News: Swiss fertility drug company rises 34.2% ARES-SERONO, the Geneva group specialising in human fertility drugs, reports net income from continuing operations up 34.2 per cent in the third quarter to Dollars 21.1m or Dollars 5.63 per share. Sales grew 29.4 per cent to Dollars 214.4m, with strong performances coming from the US, Italy, France and Germany. 'We have observed a certain weakening in key European markets at the end of the quarter, due to strains on governmental reimbursement schemes,' Mr Fabio Bertarelli, chief executive, said. For the nine months ended September, net income from continuing operations rose 28.3 per cent to Dollars 59.7m or Dollars 15.94 per share. Including the gain from the sale of the over-the-counter division earlier in the year, net income was Dollars 87.8m.</p>
		</main>
</body></html>
            